[
    {
        "content": "* Women In Bio announces that Alpna Seth joins Bio-Techne's board of directors Source text for Eikon:",
        "date": "11072017",
        "name": "Bio-Techne Corp",
        "news_type": "topStory",
        "symbol": "TECH",
        "title": "BRIEF-Women In Bio announces that Alpna Seth joins Bio-Techne's board "
    },
    {
        "content": "* Q1 earnings per share view $0.88 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)",
        "date": "10312017",
        "name": "Bio-Techne Corp",
        "news_type": "topStory",
        "symbol": "TECH",
        "title": "BRIEF-Bio-Techne releases Q1 adjusted earnings per share $0.90 "
    },
    {
        "content": "* Bio-Techne adds two new directors to its board Source text for Eikon: Further company coverage:",
        "date": "10262017",
        "name": "Bio-Techne Corp",
        "news_type": "topStory",
        "symbol": "TECH",
        "title": "BRIEF-Bio-Techne adds two new directors to its board "
    },
    {
        "content": "* Bio-Techne Corp says transaction is financed through available cash on hand",
        "date": "09052017",
        "name": "Bio-Techne Corp",
        "news_type": "topStory",
        "symbol": "TECH",
        "title": "BRIEF-Bio-Techne acquires Trevigen Inc "
    },
    {
        "content": "* Bio-Techne releases a highly sensitive and specific serological assay to detect Zika virus infections",
        "date": "09062017",
        "name": "Bio-Techne Corp",
        "news_type": "topStory",
        "symbol": "TECH",
        "title": "BRIEF-Bio-Techne releases serological assay to detect Zika virus infections "
    },
    {
        "content": "* Bio-Techne Corp - Bio-Techne has entered into an exclusive license agreement with multiclonal therapeutics",
        "date": "03072017",
        "name": "Bio-Techne Corp",
        "news_type": "topStory",
        "symbol": "TECH",
        "title": "BRIEF-Bio-Techne Corp & Bio-Techne has entered into an exclusive license agreement "
    },
    {
        "content": "* Q1 earnings per share view $0.79 -- Thomson Reuters I/B/E/S",
        "date": "10312016",
        "name": "Bio-Techne Corp",
        "news_type": "topStory",
        "symbol": "TECH",
        "title": "BRIEF-Bio-Techne reports Q1 GAAP earnings per share $0.44 "
    },
    {
        "content": "* On July 28  2016  Bio-Techne Corp entered into a credit agreement - sec filing",
        "date": "08022016",
        "name": "Bio-Techne Corp",
        "news_type": "topStory",
        "symbol": "TECH",
        "title": "BRIEF-Bio-Techne signs credit agreement "
    },
    {
        "content": "* Q3 earnings per share view $0.89 -- Thomson Reuters I/B/E/S",
        "date": "05032016",
        "name": "Bio-Techne Corp",
        "news_type": "topStory",
        "symbol": "TECH",
        "title": "BRIEF-Bio-Techne posts Q3 adjusted earnings per share $1.01 "
    },
    {
        "content": "* Bio-Techne corporation acquires access to b-mogen biotechnologies' gene editing technology",
        "date": "05042016",
        "name": "Bio-Techne Corp",
        "news_type": "topStory",
        "symbol": "TECH",
        "title": "BRIEF-Bio-Techne acquires access to B-Mogen Biotechnologies' gene editing technology "
    }
]